Patents by Inventor Dietmar Paul Rabussay

Dietmar Paul Rabussay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100285040
    Abstract: Disclosed are methods of enhancing immune responses. Such methods involve the administration of vaccine compositions to different tissues to elicit an enhanced immune response. The enhanced response arises from the vaccination and boosting route of administration in two separate patient tissues, for example, by first administering a priming vaccination into skin and later administering a boost vaccination in muscle. In each case, priming and boosting, the administration of the vaccine composition is preferably carried out using contemporaneous electroporation-assisted delivery of the antigenic agent.
    Type: Application
    Filed: November 16, 2007
    Publication date: November 11, 2010
    Inventors: Iacob Mathiesen, Torunn Elisabeth Tjelle, Rune Kjeken, Dietmar Paul Rabussay, Feng Lin
  • Publication number: 20100249488
    Abstract: This invention provides a novel method of tissue electroporation that eliminates the need for electrodes that conduct electricity to the tissues. This invention creates electric currents and fields sufficient for porating cell membranes for improving the delivery of polynucleotides such as plasmid and linear DNA and RNA constructs, and polypeptides such as antigen protein constructs into mammalian eucaryotic cells purely by magnetic field pulses that does not require the use of contacting electrodes to conduct electric or ionic current. This invention thus provides a method for improving transfection and immunogenicity of pharmaceutical substances without direct contact with a living body, and may be called magnetopermeabilization. A concomitant aspect of the invention is the method by which a drug such as a solution containing DNA is delivered to a targeted tissue bed that is optimal in conjunction with magnetopermeabilization for maximal transgene expression and drug effect.
    Type: Application
    Filed: March 26, 2010
    Publication date: September 30, 2010
    Applicant: MagneGene, Inc.
    Inventors: Thomas Joseph Kardos, Dietmar Paul Rabussay